LGND supply chain intelligence for Ligand Pharmaceuticals Incorporated: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Ligand Pharmaceuticals Incorporated (LGND) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| OBIO | Orchestra BioMed Holdings, Inc. | 92% | Reciprocal relationship from OBIO graph: Reciprocal relationship from LGND graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from LGND graph: Reciprocal relationship from OBIO g… |
| VIKING-THERAPEUTICS-INC | VIKING-THERAPEUTICS-INC | 90% | Viking is also obligated to grant to the Company a non-exclusive, worldwide, royalty-bearing, sublicensable license under any Patent Rights and Know-How Controlled by Viking |
| AGEN | Agenus Inc. | 72% | Reciprocal relationship from AGEN graph: Reciprocal relationship from LGND graph: Reciprocal relationship from AGEN graph: — 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortizatio… |
| ANEB | Anebulo Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ANEB graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ANEB graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ANEB g… |
| CRMD | CorMedix Inc. | 72% | Reciprocal relationship from CRMD graph: .S. market since 2015. Market Opportunity MINOCIN IV addresses a defined but persistent market opportunity within the U.S. hospital anti-infectives market, pa… |
| CURX | Curanex Pharmaceuticals Inc | 72% | Reciprocal relationship from CURX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CURX g… |
| DNTH | Dianthus Therapeutics, Inc. | 72% | Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net … |
| ELUT | Elutia Inc. | 72% | Reciprocal relationship from ELUT graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ELUT graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ELUT g… |
| LGNZZ | LGNZZ | 72% | Reciprocal relationship from LGNZZ graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LGNZZ graph: Accrued financial royalty asset purchases $ $ Accrued fixed asset purchase… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LLY graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LLY grap… |
| LONA | LeonaBio, Inc. | 72% | Reciprocal relationship from LONA graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LONA graph: an adequate number of suitable patients to participate in a clinical trial o… |
| OABIW | OmniAb, Inc. | 72% | Reciprocal relationship from OABIW graph: sed consolidated financial statements. 7 Table of Contents OMNIAB, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) 1. Organization and … |
| OVID | Ovid Therapeutics Inc. | 72% | Reciprocal relationship from OVID graph: ndensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’… |
| PLX | Protalix BioTherapeutics, Inc. | 72% | Reciprocal relationship from PLX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PLX graph: e Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state … |
| PTHS | Pelthos Therapeutics Inc. | 72% | Reciprocal relationship from PTHS graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PTHS graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PTHS g… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: eements 6 % 2 % Accounts Receivable Accounts receivable consists of amounts billed to the Company’s collaboration partners for cost reimbursements for researc… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGND graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGND graph: Reciprocal relationship from SNYN… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical… |
| XOMA | XOMA Royalty Corporation | 72% | Reciprocal relationship from XOMA graph: Item 4. Mine Safety Disclosures 70 Item 5. Other Information 70 Item 6. Exhibits 71 Signatures 74 2 Table of… |
| PVLA | Palvella Therapeutics, Inc. | 62% | Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an inve… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AGEN | Agenus Inc. | 92% | Reciprocal relationship from AGEN graph: Reciprocal relationship from LGND graph: Reciprocal relationship from AGEN graph: Pursuant to the terms of the Ligand Purchase Agreement, Ligand will receive … |
| VKTX | Viking Therapeutics, Inc. | 92% | Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX g… |
| CAPVAXIVE | CAPVAXIVE | 90% | Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| FILSPARI | FILSPARI | 90% | Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| KYPROLIS | KYPROLIS | 90% | Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| OHTUVAYRE | OHTUVAYRE | 90% | Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| PARTNERS | PARTNERS | 90% | We rely on our partners' earning releases and other information from our partners to determine the sales of our partners' products and to estimate the related royalty revenues. |
| RYLAZE | RYLAZE | 90% | Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| SNYNF | Sanofi | 90% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGND graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGND graph: Reciprocal relationship from SNYN… |
| TERIPARATIDE-INJECTION | TERIPARATIDE-INJECTION | 90% | Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| VAXNEUVANCE | VAXNEUVANCE | 90% | Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| LONA | LeonaBio, Inc. | 80% | Reciprocal relationship from LONA graph: granting the Company exclusive licenses and rights to develop, manufacture and commercialize oral forms of the selective estrogen-receptor modulator known as … |
| XI-AN-XINTONG | XI-AN-XINTONG | 80% | Contract revenue and income decreased by $4.3 million, or (97)%, to $0.1 million in Q1 2026 compared to $4.4 million in Q1 2025, primarily due to a regulatory milestone tied to Xi’an Xintong’s Xinshu… |
| ANEB | Anebulo Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ANEB graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ANEB graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ANEB g… |
| BSX | Boston Scientific Corporation | 72% | Reciprocal relationship from BSX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from BSX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from BSX grap… |
| CRMD | CorMedix Inc. | 72% | Reciprocal relationship from CRMD graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CRMD graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CRMD g… |
| CURX | Curanex Pharmaceuticals Inc | 72% | Reciprocal relationship from CURX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CURX g… |
| DNTH | Dianthus Therapeutics, Inc. | 72% | Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net … |
| ELUT | Elutia Inc. | 72% | Reciprocal relationship from ELUT graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ELUT graph: Reciprocal relationship from LGND graph: Reciprocal relationship from ELUT g… |
| LGNZZ | LGNZZ | 72% | Reciprocal relationship from LGNZZ graph: Accrued financial royalty asset purchases $ $ Accrued fixed asset purchases $ $ Unrealized gain (loss) on AFS investments, net of tax $ ( ) $ See accompanyin… |
| LLY | Eli Lilly and Company | 72% | entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States in 2026, or … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LLY graph: Reciprocal relationship from LGND graph: entered into a settlement agreement w… |
| OBIO | Orchestra BioMed Holdings, Inc. | 72% | Reciprocal relationship from OBIO graph: Reciprocal relationship from LGND graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from LGND graph: Reciprocal relationship from OBIO g… |
| OVID | Ovid Therapeutics Inc. | 72% | tia”) in September 2023) in 2017, Ovid Therapeutics Inc. (“Ovid”) in October 2023, Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) in November 2023, and from certain ensifentrine inventors in… |
| OVID | Ovid Therapeutics Inc. | 72% | Reciprocal relationship from OVID graph: Reciprocal relationship from LGND graph: tia”) in September 2023) in 2017, Ovid Therapeutics Inc. (“Ovid”) in October 2023, Tolerance Therapeutics, Inc. (“Tol… |
| PLX | Protalix BioTherapeutics, Inc. | 72% | Reciprocal relationship from PLX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PLX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PLX grap… |
| PTHS | Pelthos Therapeutics Inc. | 72% | Reciprocal relationship from PTHS graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PTHS graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PTHS g… |
| PVLA | Palvella Therapeutics, Inc. | 72% | Reciprocal relationship from PVLA graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PVLA g… |
| PVLA | Palvella Therapeutics, Inc. | 72% | ,115 23,401 22,262 Less accumulated depreciation and amortization ( 8,268 ) ( 6,655 ) $ 15,133 $ 15,607 Depreciation of equipment is computed using the straight-line method over the estimated useful … |
| SNYNF | Sanofi | 72% | entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States in 2026, or … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LGND-DEBT-10688 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| LGND-DEBT-10687 | Warrants outstanding: 3264643 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| LGND-DEBT | Debt stack $452.0M | 90% | Market cache reports total debt of $452.0M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LGND-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 360 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| BSX | Boston Scientific Corporation | 100.00 | 1 | ['customer'] |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 |